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examinations is apparent. Moreover, 
patients with high grade dysplasia, 
despite acid suppression, should be 
considered for oesophagectomy if the 
patient is fit for surgery, or endoscopic 
ablation if surgery is contraindicated4.
In China, oesophageal cancer is 
ranked second after gastric cancer as 
the leading cause of cancer death, with 
the predominant factor being related 
probably to diet, mainly micronutrient 
deficiencies, low levels of protective 
factors that occur in fresh fruit and 
vegetables, and consumption of food 
containing high levels of initiating 
carcinogens such as nitrosamines. 
Being highly prevalent, public mass 
screening in adults over 35 years, 
using balloon cytology or gastric occult 
blood bead tests, was initiated in 1974. 
Those with dysplasia or cancer went 
on to have an upper endoscopy and 
treatment. Those with normal mucosa 
were screened every 1-2 years. Having 
screened over 160 million participants 
between 1973 and 1999, this cohort’s 
5 year survival rate has increased 
from 10% to 90%, thereby reducing 
mortality in this high-risk population 
using inexpensive, simple and effective 
methods5.   (to be continued)
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In many countries cervical cancer is the commonest gynaecological 
cancer.  In Malta and in the United 
States, it is the third most common 
gynaecological cancer.  Countries 
which introduced organised cervical 
screening programmes saw a 
dramatic decrease in incidence and 
mortality from this cancer.1  In Malta 
however, its incidence and mortality 
has remained relatively constant in 
the last few decades, in keeping 
with the fact that we lack a national 
organised call and re-call cervical 
screening programme.2   Our cervical 
screening is largely opportunistic 
and most of it is carried out in the 
private sector.  Although incidence 
and mortality has not decreased, 
our present imperfect screening 
must however have prevented a 
significant rise in incidence and 
mortality, because the detection 
(and treatment) of premalignant 
cervical lesions has risen over recent 
decades, in keeping with increased 
sexual promiscuity. 
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Infection with high-risk strains of 
human papillomavirus (HPV) has been 
identified as the underlying cause 
of cervical cancer.3 However, HPV 
infection is usually transient and quite 
common in the general population, with 
a lifetime cumulative risk of at least 
80%.4,5  Persistent infection by high-
risk HPV (most commonly subtypes 
16, 18, 31 and 45) is a prerequisite for 
development of cervical intraepithelial 
neoplasia (CIN – premalignant 
lesion), and subsequent malignant 
transformation to invasive cervical 
cancer.  HPV is a necessary precursor 
of CIN but does not act alone – host 
factors such as age, immune status,6 
history of other sexually transmitted 
diseases7 and smoking8 are cofactors.
CIN lesions are usually diagnosed 
in women younger than 40 years, 
which is 10 to 15 years earlier than 
in women diagnosed with invasive 
cervical cancer, this age gap indicating 
a long latency period for malignant 
transformation.  Low-grade CIN is 
usually diagnosed in women in their 
20s, whereas high-grade CIN is usually 
diagnosed in women aged 25 to 35 
years, and invasive cancer is most 
often diagnosed in women older 
than 40 years.
About 70% of cervical 
cancer is caused by HPV 
types 16 and 18.  Vaccines 
have been developed against 
both HPV 16 and 18 and 
against low-risk HPV 6 and 
11, the latter two being 
responsible for the majority 
of genital warts.  
Although it is not clear 
how long immunity will 
last after vaccination, the 
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data suggest at least 5 to 6 years.9,10  
Nevertheless vaccinated women are 
still at risk for cervical cancer related 
to other less common high-risk 
HPV types, and it is imperative that 
vaccinated women should continue 
screening.  
An understanding of the natural 
history of low-grade and high-grade 
CIN lesions is central to clinical 
management of abnormal cervical 
cytology.  Low-grade CIN lesions 
have poor reproducibility between 
pathologists, some not even making 
a distinction between uncomplicated 
HPV infection changes and low-grade 
CIN. Unfortunately this is encouraged 
by the Bethesda System whose low-
grade squamous intraepithelial lesion 
(LSIL) category does not distinguish 
between pure HPV changes and 
CIN 1.  The cellular abnormalities 
in teenage girls and women in their 
early 20s are practically always due to 
simple HPV infection uncomplicated 
by CIN, and invasive cervical cancer 
in this age-group is as rare as hen’s 
teeth.  Cytological diagnoses of 
LSIL in teenage girls may lead to 
colposcopy, which would amount to 
over-investigation that is difficult to 
justify – if this leads to cone biopsy, it 
would mean even worse management. 
Pathology consultation reports 
should communicate diagnostic 
opinion to clinicians in clear clinical 
language and not in laboratory 
jargon. It is the author’s experience 
that, if clinicians want to know 
whether their patient has simple HPV 
infection, low-grade or high-grade 
CIN, the smear report should use 
these terms, rather than koilocytosis, 
dyskaryosis, LSIL, HSIL, etc., to 
avoid any possible misunderstanding 
as to the exact pathology the 
cytology report is suggesting. If the 
pathologist is uncertain whether 
the cellular abnormalities are due to 
non-specific inflammatory reactive 
hyperplasia, HPV infection or CIN, 
this uncertainty should be stated 
in plain English – to the author, 
Bethesda System diagnostic 
categories such as “atypical cells of 
uncertain significance” suggest an 
inexperienced beginner is issuing the 
cytology consultation reports. 
Clear laboratory reporting should 
be complimented by adequate clinical 
information on smear request forms 
– why?  The smears which should be 
examined most carefully are those from 
women in their 30s and 40s without 
a history of regular normal smears, 
in an effort to cut down, as much as 
possible, the ever-present risk of the 
dreaded false-negative smear in a 
patient with invasive cervical cancer. 
The cervical cytology request form 
should therefore, ideally, be designed to 
prompt the clinician to offer some basic 
clinical information about the patient, 
namely, age and whether or not she 
has a history of regular normal smears.  
Information about parity is irrelevant 
because this is not related to risk of 
cervical cancer, as believed several 
decades ago.  
The screening methods available 
are the conventional smear, liquid-
based cytology (LBC) and HPV DNA 
(high-risk, not type specific) plus 
cytology.  The reported sensitivity of a 
single conventional smear varies from 
32 to 92%,11 which prompted the early 
guidelines for annual smear screening.  
LBC has a similar performance 
record to the conventional smear, 
and meta-analysis of eight studies 
demonstrated similar sensitivity 
and specificity between the two 
technologies.12 Thus, either method 
is an acceptable screening test, 
and raises the question whether the 
significantly increased cost of LBC 
is justified.  Furthermore, from the 
author’s experience, the LBC technique 
leads to under-diagnosis of bacterial 
vaginosis – a not insignificant condition 
as it may require antibiotic treatment.13  
HPV DNA testing, in combination 
with cytology, is useful in identifying 
patients with difficult-to-interpret 
cytological abnormalities who are at 
increased risk for neoplasia.14 In this 
patient category, the negative predictive 
value of the HPV DNA (high-risk, not 
type specific) for CIN 2 and CIN 3, or 
worse, as confirmed by colposcopy, is 
99%.15 Women testing negative on both 
cytology and HPV DNA can increase 
their screening interval to 3 years.16
A biomarker that distinguishes 
between low-risk transient HPV 
infections from high-risk persistent 
infection might prove more accurate 
than HPV DNA testing in the above 
category of women with equivocal 
cytology.  The tumour suppressor gene 
p16 is upregulated in high-risk HPV-
transformed cells, and 95% sensitivity 
and 84% specificity in detecting high-
grade CIN has been reported.17   
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